Home  |  Contact

UniProtKB/Swiss-Prot Q9NRI5: Variant p.Arg264Gln

Disrupted in schizophrenia 1 protein
Gene: DISC1
Variant information

Variant position:  264
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:  LB/B
The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change:  From Arginine (R) to Glutamine (Q) at position 264 (R264Q, p.Arg264Gln).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:  Change from large size and basic (R) to medium size and polar (Q)
The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:  1
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Other resources:  
Links to websites of interest for the variant.



Sequence information

Variant position:  264
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:  854
The length of the canonical sequence.

Location on the sequence:   EMGAKAASLDGPHEDPRCLS  R PFSLLATRVSADLAQAARNS
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Residue conservation: 
The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         EMGAKAASLDGPHEDPRCLSRPFSLLATRVSADLAQAARNS

Mouse                         EMAAEASSSDRPHGDPRHL-WTFSLHAAPGLADLAQVTRSS

Rat                           EMAAEGSGSDRPHGEPRHL-WTFSLHAAPGLVDLAQGTRSN

Sequence annotation in neighborhood:  
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.

TypePositionsDescription
Chain 1 – 854 Disrupted in schizophrenia 1 protein
Region 1 – 292 Interaction with MAP1A
Alternative sequence 23 – 372 Missing. In isoform 11.


Literature citations

Disruption of two novel genes by a translocation co-segregating with schizophrenia.
Millar J.K.; Wilson-Annan J.C.; Anderson S.; Christie S.; Taylor M.S.; Semple C.A.M.; Devon R.S.; St Clair D.M.; Muir W.J.; Blackwood D.H.R.; Porteous D.J.;
Hum. Mol. Genet. 9:1415-1423(2000)
Cited for: NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORM 1); VARIANTS GLN-264 AND CYS-704;

Evolutionary constraints on the Disrupted in Schizophrenia locus.
Taylor M.S.; Devon R.S.; Millar J.K.; Porteous D.J.;
Genomics 81:67-77(2003)
Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 3 AND 4); VARIANT GLN-264;

Characterization of cDNA clones in size-fractionated cDNA libraries from human brain.
Seki N.; Ohira M.; Nagase T.; Ishikawa K.; Miyajima N.; Nakajima D.; Nomura N.; Ohara O.;
DNA Res. 4:345-349(1997)
Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2); VARIANT GLN-264;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.